Geron Corporation (GERN) saw its loss narrow to $7.18 million, or $0.05 a share for the quarter ended Mar. 31, 2017. In the previous year period, the company reported a loss of $8.84 million, or $0.06 a share.     

Revenue during the quarter dropped 28.30 percent to $0.54 million from $0.75 million in the previous year period.

Operating loss for the quarter was $7.49 million, compared with an operating loss of $9.08 million in the previous year period.

"As a result of the second internal data reviews that were completed in April for the imetelstat clinical trials in myelodysplastic syndromes and myelofibrosis, both trials are continuing unmodified. For IMerge, the next step is a decision regarding the Phase 3 portion of the trial. If Janssen decides to move forward, we expect the Phase 3 portion to be open to patient enrollment in the fourth quarter. For IMbark, we expect Janssen to evaluate maturing data from the trial during the next year, including an assessment of overall survival," said John A. Scarlett, M.D., Geron's president and chief executive officer. "We continue to be pleased by the commitment to imetelstat shown by our colleagues at Janssen. Their conduct of these internal data reviews has highlighted to us the care and professional development expertise they are applying to this innovative drug."

Days sales outstanding went down to 101 days for the quarter compared with 111 days for the same period last year.